Kaizen in action
Taken on Jan 1st 2023 – a bright new path forward?
Kaizen is the Japanese word for continuous improvement.
It’s all very well companies producing their first blockbuster in oncology, but what then?
The real mark of success in my view is being able to sustain their effort to build a life cycle management portfolio lasting over time, so in effect you generate many more options and opportunities for success over the long run. This is much harder to achieve.
I think many folks were quite curious to see what would happen to the promising early stage Celgene pipeline once it transferred to BMS. Would the march continue beyond the IMiDs, or would it all wither and die on the vine?
We last took stock of their progress at ASH20 prior to the approvals of ide-cel and liso-cel. In the two years since then much has happened – both on the approval front and also with the products coming along further behind.
It’s time for a look at how things are progressing, with some surprises in store…
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
